Cleveland Clinic

Stay up-to-date with the latest in FDA decisions, trial readouts, and key clinician insights from all corners of endocrinology.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.

Luke Laffin, MD, discusses his secondary analysis of the phase 2 KARDINAL trial, which demonstrated substantial improvements in uncontrolled hypertension.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.

Ashish Sarraju, MD, discusses phase 1 data showing a single dose of Kylo-11 durably reduced lipoprotein(a) through 48 weeks.

Luke Laffin, MD, discusses 1-year data showing CTX310 produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides.

Steven Nissen, MD, shares key takeaways on AAV8, CTX310, and Kylo-11 gene and molecular therapies presented at ESC Congress 2026.

CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

In this episode, co-hosts Isaacs and Bellini are joined by Eden Miller, DO, and Davida Kruger, NP, to discuss the FDA's recent clearance of the FreeStyle Libre Duo ketone monitor.

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

This episode discusses the recent results from trials of IcoSema and a new highly concentrated insulin aspart.

Academic pulmonologists from Mass General, Duke, and Cleveland Clinic discuss biologic selection, mucus plugging, and more.

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

Once-weekly insulin icodec hits US pharmacies, simplifying basal dosing for type 2 diabetes with new titration rules and promising A1c results.

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

This episode covers the recently announced topline data from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials, as well as a study investigating online GLP-1 sales.

Highlights include an exploratory nerandomilast mortality analysis, the first North American bronchiectasis guideline from CHEST, and more.

Angelika Erwin, MD, PhD, joins the podcast to discuss diagnosing and managing EPP and XLP on ABCs in Dermatology.

This episode covers the recent commercial availability of the Pivot patch pump and the upcoming 7-day bolus patch from CeQur.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover recent data released by Eledon regarding tegoprubart for type 1 diabetes.

This episode covers the recent release of new data on Eledon’s tegoprubart for islet cell transplantation in patients with T1D.

This episode covers the recent trial of the Signos weight loss platform, indicating weight loss that could challenge GLP-1 receptor agonists.

This episode covers recent approvals and updated indications allowing more treatment options for children with diabetes.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Ketan Dhatariya, MD, PhD, MS, joins the show to discuss how therapies for diabetes have evolved in the UK in comparison to the US.